Clinical Trial Litigation: from Informed Consent Failures to Causation Defense

Federal informed consent regulations under 21 CFR Part 50 require the consent document and process to disclose the study's purpose, its expected duration, all foreseeable risks and discomforts, alternative treatments available outside the trial, the extent to which records will remain confidential, and the voluntary nature of participation including the right to withdraw without penalty. Pharmaceutical regulatory compliance counsel must review every informed consent form against the applicable regulatory requirements and the disclosure standards applied in prior litigation involving the same or comparable investigational products.

A researcher or contract research organization that deviates from the protocol's patient selection criteria, dosing schedule, or safety monitoring requirements without documented scientific justification has breached the applicable standard of care. Pharmaceutical law counsel must obtain the complete trial master file, including all monitoring visit reports, protocol amendment histories, and deviation logs, since the pattern of deviations frequently reveals systematic rather than isolated failures.

General causation is established through peer-reviewed epidemiological studies and biological plausibility of the proposed injury mechanism, while specific causation, meaning that the investigational product actually caused this particular plaintiff's injury, requires a differential diagnosis that rules out alternative causes and applies the general causation evidence to the plaintiff's individual circumstances. Medical malpractice litigation counsel must retain Daubert-qualified experts on both general and specific causation, since a causation expert failing to satisfy Federal Rule of Evidence 702 will result in case dismissal before the jury evaluates the merits.

Good clinical practice requires all trial data to be attributable, legible, contemporaneous, original, and accurate, and any discrepancy between case report forms, source documents, and the study database that cannot be explained by an audit trail creates a data integrity deficiency. FDA regulatory compliance counsel must obtain all FDA inspection findings, warning letters, and Form 483 observations related to the trial, since regulatory findings of data integrity problems create a rebuttable presumption in subsequent civil litigation that the sponsor knew of systemic data quality problems before the adverse event at issue.

A participant who was fully informed of a specific risk that materialized assumes that risk as a matter of law when the disclosure was adequate and the participant voluntarily chose to enroll. Product liability counsel defending a sponsor must confirm that the consent document explicitly identified the specific adverse event type that occurred, that the participant had adequate time and capacity to understand the disclosure, and that no post-consent pressure was applied to prevent the participant from withdrawing.

The learned intermediary doctrine applies with greater force to clinical trial investigators who have received comprehensive investigator brochure disclosures of all known risks, and any design defect claim must be evaluated against the risk-benefit profile appropriate to an investigational compound. Defective drugs defense counsel must confirm that the investigator's brochure contained all material risk information available at the time of the injury and that the investigator was required to communicate that information to the participant through the informed consent process.

Class certification in clinical trial cases faces predominance challenges because each participant's causation and damages depend on individual medical history, doses received, and the specific adverse event experienced. Mass tort counsel must challenge class certification on predominance grounds while simultaneously evaluating whether a structured settlement that compensates demonstrably injured participants without creating precedential admissions offers a better outcome than protracted multi-district litigation.

A clinical trial sponsor whose trial generates safety signals, protocol deviations, or data integrity findings must address those issues through FDA's post-trial pharmacovigilance reporting requirements and must update the investigator's brochure and consent documents for ongoing studies, since a failure to act on known safety signals creates enhanced liability for any subsequent participant injury. Healthcare compliance counsel must monitor all FDA post-market surveillance obligations and manage the statute of limitations for late-presenting adverse events.